Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BenevolentAI Goes Public In Europe’s Largest SPAC

Valued at €1.5bn

Executive Summary

The UK computational medicines specialist is listing on the Euronext Amsterdam after linking up with healthcare-focused special purpose acquisition corporation Odyssey which is advised by former Sanofi CEO Olivier Brandicourt.

You may also be interested in...



BenevolentAI Still Bullish As CEO Shields Steps Down

BenevolentAI has added Merck KGaA to its list of partners but the UK firm is looking for a new CEO after Joanna Shields decided to leave as a major restructuring continues.

BenevolentAI Slashes Jobs And Drug Programs

The UK firm, which uses artificial intelligence to discover and develop drugs, is hoping to save £45m by halving its workforce and trimming its pipeline.

BenevolentAI Atopic Dermatitis Drug Fails To Deliver

The UK artificial intelligence drug development expert has reported disappointing findings from a Phase II trial of lead candidate BEN-2293 in atopic dermatitis.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC145536

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel